Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
P/E ratio for Talaris Therapeutics, Inc. (TALS)
P/E ratio as of 2022: -0.06
According to Talaris Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.06. At the end of 2021 the company had a P/E ratio of -0.92.
P/E ratio history for Talaris Therapeutics, Inc. from 2019 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -0.06 |
| 2021 | -0.92 |
| 2020 | -0.48 |
| 2019 | -0.58 |